PuSH - Publikationsserver des Helmholtz Zentrums München

Roehnisch, T.* ; Then, C.* ; Nagel, W. ; Blumenthal, C.* ; Braciak, T.* ; Donzeau, M.* ; Boehm, T.* ; Flaig, M.* ; Bourquin, C.* ; Oduncu, F.*

Phage idiotype vaccination: First phase I/II clinical trial in patients with multiple myeloma.

J. Transl. Med. 12:119 (2014)
Verlagsversion Volltext DOI
Open Access Gold
Creative Commons Lizenzvertrag
Background: Multiple myeloma is characterized by clonal expansion of B cells producing monoclonal immunoglobulins or fragments thereof, which can be detected in the serum and/or urine and are ideal target antigens for patient-specific immunotherapies. Methods: Using phage particles as immunological carriers, we employed a novel chemically linked idiotype vaccine in a clinical phase I/II trial including 15 patients with advanced multiple myeloma. Vaccines composed of purified paraproteins linked to phage were manufactured successfully for each patient. Patients received six intradermal immunizations with phage idiotype vaccines in three different dose groups. Results: Phage idiotype was well tolerated by all study participants. A subset of patients (80% in the middle dose group) displayed a clinical response indicated by decrease or stabilization of paraprotein levels. Patients exhibiting a clinical response to phage vaccines also raised idiotype-specific immunoglobulins. Induction of a cellular immune response was demonstrated by a cytotoxicity assay and delayed type hypersensitivity tests. Conclusion: We present a simple, time-and cost-efficient phage idiotype vaccination strategy, which represents a safe and feasible patient-specific therapy for patients with advanced multiple myeloma and produced promising anti-tumor activity in a subset of patients.
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Korrespondenzautor
Schlagwörter Patient-specific Immunotherapy ; Phage Idiotype Vaccination ; Multiple Myeloma ; Phase I/ii Clinical Trial ; Paraprotein; B-cell Lymphoma; Humoral Immune-response; Pulsed Dendritic Cells; Fc-receptor Genotype; Hla Class-i; Follicular Lymphoma; Antibody-responses; Filamentous Phage; T-cells; Peptide
ISSN (print) / ISBN 1479-5876
e-ISSN 1479-5876
Zeitschrift Journal of Translational Medicine
Quellenangaben Band: 12, Heft: 1, Seiten: , Artikelnummer: 119 Supplement: ,
Verlag BioMed Central
Verlagsort London
Nichtpatentliteratur Publikationen
Begutachtungsstatus Peer reviewed